Glycation Reversal Enzymes (AGE Breakers)
An emerging class of engineered enzymes designed to break down advanced glycation end products (AGEs) - sugar-modified adducts that accumulate irreversibly on long-lived proteins over decades and stiffen tissue, drive RAGE-mediated inflammation, and are considered a chemical hallmark of aging.
Evidence Summary
Peer-reviewed but strictly bench-stage. Nature Communications 2026 (Trabosh et al., Revel Pharmaceuticals with Calico Life Sciences) reports CMLase, an enzyme engineered by directed evolution across more than 500 million variants of a bacterial glycine oxidase scaffold, which specifically oxidizes CML and restores native lysine. CMLase removed up to 97% of CML from model proteins in vitro and reduced CML burden by roughly 45-70% in ex vivo human lens, skin and artery tissue from elderly donors. This is the first credible demonstration that a glycation adduct long considered chemically irreversible is enzymatically repairable. It is emphatically NOT a therapy: all human data are ex vivo explanted tissue, with no in vivo administration, no delivery route, no pharmacokinetics, no immunogenicity data and no functional or clinical endpoint. Earlier small-molecule AGE breakers (alagebrium/ALT-711) generated similar excitement in the 2000s and failed to translate. Note also that CML is one of several AGE species, and which AGEs actually matter in aging versus diabetes remains unsettled.
Evidence Scale
Mechanism of Action
Reducing sugars react non-enzymatically with protein lysine residues to form stable AGE adducts, of which N-epsilon-carboxymethyl-lysine (CML) is the most abundant in aged tissue. These adducts cross-link extracellular matrix proteins, stiffening lens, skin and arterial wall, and act as ligands for RAGE, sustaining chronic inflammation and oxidative stress. Engineered oxidases can be directed to specifically oxidize the adduct and restore the native lysine, chemically reversing damage that endogenous systems cannot address.
Who Is This For?
No patient is currently a candidate. Relevant only as background for patients asking about glycation, AGEs, or dietary AGE reduction.
Protocol & Dosing
Dose
Not applicable - preclinical
Frequency
Not applicable
Duration
Not applicable
Protocol Summary
No clinical protocol exists. There is no available product, no dosing, and no route of administration. This page tracks a research program, not an offering.
Interactions & Precautions
Contraindications
- Not clinically available - any product marketed as an AGE-breaker enzyme therapy should be treated as unvalidated
Potential Risks
- •Immunogenicity of a bacterial-derived enzyme is unassessed
- •Delivery to cross-linked extracellular matrix is an unsolved problem
- •Historical precedent (alagebrium) of AGE-breaker programs failing in human trials
- •Reversing a chemical marker may not translate into functional benefit
Potential Side Effects
Practitioner Notes
Clinical annotations from Dr. Goel
Useful to have a grounded answer when patients raise AGEs. The honest framing: this is the most encouraging AGE result in twenty years and it is still explanted-tissue chemistry with no delivery route. In the meantime, the only evidence-supported levers on AGE burden remain glycemic control, avoiding high-heat dry cooking methods, and not smoking - none of which reverse existing adducts. Do not let this paper be used to justify commercial "AGE-breaker" supplements, which have no relationship to the engineered enzyme described here.
Dr. Sanjeev Goel
Chief Medical Officer, Peak Human
Cost & Access
Cost Range
Not commercially available
Accessibility
Availability varies by location
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation